Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542372 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3541326 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3542623 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3544390 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3118906 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL21876977 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3542475 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL12237539 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3541651 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3543712 | 1.00 | TSHR (0.42) | TSHRALDH1A1TP53HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | claimed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | claimed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | claimed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | claimed |
| EP-4364727-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240041889-A1 | COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2024-02-08 | — | — | US | disclosed |
| EP-3762386-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3498712-B1 | SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF | JIANGSU YAYO BIOTECHNOLOGY CO LTD (CN) | 2024-01-03 | — | — | EP | disclosed |
| US-20220056033-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11124515-B2 | Adenosine receptor antagonists and uses thereof | TEON THERAPEUTICS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-11053205-B2 | Phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-07-06 | — | — | US | disclosed |
| EP-1744394-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1339686-A2 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-6525077-B2 | Antiproliferative agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-02-25 | — | — | US | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002042276-A1 | QUARTERNARY PROFORMS OF TERTIARY AMINE CONTAINING COMPOUNDS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| US-5387354-A | Polyalkylene glycol polycarbonate based lubricant oil composition | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| US-5350839-A | Esters to improve taste and remove bitterness | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1994-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | TSHR 134/4885ALDH1A1 1071/4885TP53 2757/4885 |
| US-20220056033-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | TSHR 209/4885ALDH1A1 817/4885TP53 3948/4885 |
| US-20240041889-A1 | COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | TSHR 343/4885ALDH1A1 667/4885TP53 140/4885 |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | TSHR 4285/4885ALDH1A1 371/4885TP53 18/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | TSHR 1145/4885ALDH1A1 782/4885TP53 4872/4885 |
| US-11053205-B2 | Phenazine derivatives as antimicrobial agents | ROS1, NOX4, PRDX3 | TSHR 1451/4885ALDH1A1 701/4885TP53 2115/4885 |
| US-11124515-B2 | Adenosine receptor antagonists and uses thereof | ADORA2B, ADORA2A, ADORA3 | TSHR 218/4885ALDH1A1 634/4885TP53 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.